- Accure Acne’s groundbreaking Accure Laser System is the first commercially developed energy-based device that selectively targets and neutralizes overactive sebaceous glands
- The innovative technology is expected to position Accure as a disruptor on the vast global market of acne treatments
- By targeting only overactive glands, the system offers enhanced efficacy and a durable response; safety and efficacy have been confirmed by four IBR-approved clinical trials
- An early adopter program is already underway in the European Union, with the first orders received and delivered in Italy in Q2 2021; a broader commercial launch in several European countries is currently slated for H2 2021
- The company restarted a pivotal acne study in January 2021, with initial results expected in early 2022; this study will be essential for FDA approval in view of beginning U.S. commercialization in 2022
- Accure Acne boasts highly experienced management and scientific teams, leveraging decades of expertise in the aesthetics and medical device markets
- The company was co-founded by one of the most influential scientists in the field of energy-based devices and the co-developer of microscopic target-selective laser therapy
Accure Acne is a privately-owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution.
Leveraging the extensive experience of its management and scientific teams, paired with a clear go-to-market strategy and commercialization and regulatory expertise, Accure remains committed to developing a…
NOTE TO INVESTORS: The latest news and updates relating to Accure Acne are available in the company’s newsroom at https://ibn.fm/ACNE
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
